Metformin associated lactic acidosis: a case series of 28 patients treated with sustained low-efficiency dialysis (SLED) and long-term follow-up

Background: Metformin associated lactic acidosis (MALA) is a well-known serious side effect of biguanides. However, the best treatment strategy remains a matter of debate. In the last 14 years, we observed a significant increase in hospitalizations for MALA to our Center. We report the outcomes of our clinical and therapeutic approach. Methods: This is a single-center case series. Twenty-eight patients affected with MALA and acute kidney failure admitted between January 2000 and September 2014 were included. We analyzed comorbidities, laboratory tests and clinical parameters at admission, at 36 h and at discharge. All patients were treated with sustained low-efficiency dialysis (SLED) until normalization of serum lactate (≤ 3 mmol/L), bicarbonate (between 20 and 25 mmol/L) and potassium (between 4.0 and 5.1 mmol/L). Results: The mortality rate was 21.4%, with all of the events occurring within 24 h from admission, and before or during the first hemodialysis treatment. Precipitating causes included; acute dehydration (86.4%), systemic inflammatory response syndrome (SIRS) (57.1%), sepsis (10.7%), nephrolithiasis (14.6%) and exposure to iodinated contrast (7.1%). No further episodes of lactic acidosis were described after discontinuing the drug over a mean follow-up of 27.2 months. Furthermore, while in 2010, we had a peak incidence of MALA of 76.8 cases per 100,000 patients on metformin, this rate fell after an education campaign conducted by specialists on the proper usage of metformin in patients at risk of MALA. Although the fall in incidence after the educational program was not necessarily causal, in 2014 the incidence was 32.9/100,000. Conclusions: We report an improved mortality rate in patients affected with MALA and acute kidney injury treated with SLED compared with other series published in literature. Rapid introduction of effective hemodialysis is critical in improving outcomes.

[1]  E. Dimagno,et al.  National Institute of Diabetes and Digestive and Kidney Diseases , 2020, Definitions.

[2]  A. Sharif,et al.  Metformin and other antidiabetic agents in renal failure patients. , 2015, Kidney international.

[3]  R. Grant,et al.  Trends in the Evidence Level for the American Diabetes Association's “Standards of Medical Care in Diabetes” From 2005 to 2014 , 2014, Diabetes Care.

[4]  J. Halcox,et al.  Can people with type 2 diabetes live longer than those without? A comparison of mortality in people initiated with metformin or sulphonylurea monotherapy and matched, non‐diabetic controls , 2014, Diabetes, obesity & metabolism.

[5]  Michael J. MacDonald,et al.  Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase , 2014, Nature.

[6]  A. Protti,et al.  Metformin accumulation: Lactic acidosis and high plasmatic metformin levels in a retrospective case series of 66 patients on chronic therapy , 2014, Clinical toxicology.

[7]  L. Pani,et al.  Metformin-associated lactic acidosis requiring hospitalization. A national 10 year survey and a systematic literature review. , 2013, European review for medical and pharmacological sciences.

[8]  A. Khwaja.  KDIGO Clinical Practice Guidelines for Acute Kidney Injury , 2012, Nephron Clinical Practice.

[9]  M. Singer,et al.  Oxygen consumption is depressed in patients with lactic acidosis due to biguanide intoxication , 2010, Critical care.

[10]  G. Nichols,et al.  Secondary Failure of Metformin Monotherapy in Clinical Practice , 2009, Diabetes Care.

[11]  L. Marroquin,et al.  Biguanide-induced mitochondrial dysfunction yields increased lactate production and cytotoxicity of aerobically-poised HepG2 cells and human hepatocytes in vitro. , 2008, Toxicology and applied pharmacology.

[12]  H. Howlett,et al.  Metformin therapy and clinical uses , 2008, Diabetes & vascular disease research.

[13]  Jianmin Tian,et al.  Acute kidney injury criteria predict outcomes of critically ill patients* , 2008, Critical care medicine.

[14]  Michael M. Engelgau,et al.  Prevalence of Diabetes and Impaired Fasting Glucose in Adults in the U.S. Population , 2006, Diabetes Care.

[15]  A. Morris,et al.  Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin , 2006, Diabetologia.

[16]  U. Panzer,et al.  Combination of intermittent haemodialysis and high-volume continuous haemofiltration for the treatment of severe metformin-induced lactic acidosis. , 2004, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[17]  M. Andréjak,et al.  Kinetics of plasma and erythrocyte metformin after acute administration in healthy subjects. , 2003, Diabetes & metabolism.

[18]  H. Kusuhara,et al.  Involvement of organic cation transporter 1 in the lactic acidosis caused by metformin. , 2003, Molecular pharmacology.

[19]  J. Lalau,et al.  Lactic acidosis in metformin therapy: searching for a link with metformin in reports of ‘metformin‐associated lactic acidosis’ , 2001, Diabetes, obesity & metabolism.

[20]  Jonathan B. Brown,et al.  Lactic Acidosis Rates in Type 2 Diabetes , 1998, Diabetes Care.

[21]  R. Holman,et al.  Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) , 1998, The Lancet.

[22]  A. Majid,et al.  Bicarbonate haemodialysis as a treatment of metformin overdose. , 1997, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[23]  R. DeFronzo,et al.  Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. , 1995, The New England journal of medicine.

[24]  M. Mullee,et al.  The Distribution and Severity of Diabetic Foot Disease: a Community Study with Comparison to a Non‐diabetic Group , 1992, Diabetic medicine : a journal of the British Diabetic Association.

[25]  R. H. Williams,et al.  Farewell to phenformin for treating diabetes mellitus. , 1975, Annals of internal medicine.

[26]  C. G. Vermeij,et al.  Metformin associated lactic acidosis: incidence and clinical correlation with metformin serum concentration measurements , 2011 .

[27]  S. Nseir,et al.  Metformin-associated lactic acidosis : A prognostic and therapeutic study * , 2009 .

[28]  W. Knaus,et al.  Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. 1992. , 2009, Chest.

[29]  E. Salpeter,et al.  Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. , 2003, The Cochrane database of systematic reviews.

[30]  J. Lalau,et al.  Lactic acidosis in metformin-treated patients. Prognostic value of arterial lactate levels and plasma metformin concentrations. , 1999, Drug safety.